| |
|
|
|
|
|
 |
| |
|
º£½ºÆ®·ÐÁ¡¾ÈÁ¦(¾È°ú¿ë¼¼ÇÁ¸Þ³ì½É¿°»ê¿°) BESTRON EYE.[Cefmenoxime HCl]
|
|
Àü¹®ÀǾàǰ | »èÁ¦
|
|
¼öÀÔÀǾàǰ
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
644901010[E02690311]
Àú°¡¾à ´ëü Àμ¾Æ¼ºê Áö±Þ ´ë»ó
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1ml(2010.10.01)(ÇöÀç¾à°¡)
\479 ¿ø/1ml(2010.06.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹é»ö ³»Áö ¿¯Àº µîȲ»öÀÇ °¡·ç°¡ µç ¹ÙÀ̾˷Π¾µ ¶§ ³ì¿© ¾²´Â Á¡¾ÈÁ¦ [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
1EYE |
| Æ÷À塤ÄÚµå´ÜÀ§ |
| ¾àǰ±Ô°Ý |
´ÜÀ§ |
Æ÷ÀåÇüÅ |
´ëÇ¥ÄÚµå |
Ç¥ÁØÄÚµå |
ºñ°í |
| 5¹Ð¸®¸®ÅÍ |
1 ¹ÙÀÌ¾Ë |
º´ |
8806449010103 |
8806449010110 |
5ml¾×Á¦+25mgºÐ¸» |
|
| ÁÖ¼ººÐÄÚµå |
126402COS
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
¾È°Ë¿°, ¸Æ¸³Á¾, ´©³¶¿°, °á¸·¿°, °ËÆÇ¼±¿°, °¢¸·¿°, °¢¸·±Ë¾ç, ¼ö¼úÈÄ °¨¿°Áõ
[Drugbank ÀÇ ¼ººÐÁ¤º¸¿¶÷] [Cefmenoxime]
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
[ÁÖ¼ººÐÄÚµå:126402COS ¿¡ µû¸¥ ½É»çÁöħ¿¶÷] º»Á¦ 1¹ÙÀ̾ËÀ» ÷ºÎ¿ëÇØ¾× 5ml¿¡ ¿ëÇØÇÏ¿© 1ȸ 1~2¹æ¿ïÀ» 1ÀÏ 4ȸ Á¡¾ÈÇÑ´Ù. Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
[Á¦Çüº°º¹¾àÁöµµ]
|
| ±Ý±â |
ÀÌ ¾à ¶Ç´Â ÀÌ ¾àÀÇ ¼ººÐ¿¡ ÀÇÇÑ °ú¹ÎÁõÀÇ º´·ÂÀÌ Àִ ȯÀÚ
|
| ½ÅÁßÅõ¿© |
- ÀÌ ¾à ¶Ç´Â ¼¼Æè°è Ç×»ý¹°Áú¿¡ °ú¹ÎÁõÀÇ º´·ÂÀÌ Àִ ȯÀÚ¿¡´Â Åõ¿©ÇÏÁö ¾Ê´Â °ÍÀ» ¿øÄ¢À¸·Î Çϳª ºÎµæÀÌÇÏ°Ô Åõ¿©ÇÒ °æ¿ì¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.
- Æä´Ï½Ç¸°°è Ç×»ý¹°Áú¿¡ °ú¹ÎÁõÀÇ º´·ÂÀÌ Àִ ȯÀÚ
- º»ÀÎ ¶Ç´Â ºÎ¸ð, ÇüÁ¦°¡ ±â°üÁöõ½Ä, ¹ßÁø, µÎµå·¯±â µîÀÇ ¾Ë·¹¸£±â Áõ»óÀ» ÀÏÀ¸Å°±â ½¬¿î üÁúÀΠȯÀÚ
|
| ÀÌ»ó¹ÝÀÀ |
1)¼ï : µå¹°°Ô ¼ïÀ» ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¹Ç·Î °üÂûÀ» ÃæºÐÈ÷ ÇÏ°í ºÒÄè°¨, ±¸³»ÀÌ»ó°¨, õ¸í, Çö±â, º¯ÀÇ, À̸í, ¹ßÇÑ µîÀÇ ÀÌ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇϰí ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÒ °Í
2)´« : ¶§¶§·Î Àڱذ¨, ¼Ò¾ç°¨, °á¸·ÃæÇ÷ µîÀÇ Áõ»óÀÌ ³ªÅ¸³ª´Â ÀÏÀÌ ÀÖÀ¸¹Ç·Î ÀÌ¿Í °°Àº Áõ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÒ °Í
|
| »óÈ£ÀÛ¿ë |
À¯»çÈÇÕ¹°(´Ù¸¥ ¼¼Æè°è Ç×»ý¹°Áú)°ú Ǫ·Î¼¼¹Ìµå µîÀÇ ÀÌ´¢Á¦¿Í º´¿ëÅõ¿©½Ã ½Åµ¶¼ºÀÌ Áõ °¡µÉ ¼ö ÀÖÀ¸¹Ç·Î ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù(ÁÖ»çÁ¦¿¡ ÇÑÇÔ). |
| Related FDA Approved Drug |
±âÁØ ¼ººÐ: CEFMENOXIME HYDROCHLORIDECEFMAX (CEFMENOXIME HYDROCHLORIDE)
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
½ÅÀå¾Ö, °£Àå¾Ö½Ã ¿ë·®Á¶Àý |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| Á¦Çüº° º¹¾àÁöµµ |
[Á¡¾È¾×] |
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Cefmenoxime¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ The bactericidal activity of cefmenoxime results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). Cefmenoxime is stable in the presence of a variety of b-lactamases, including penicillinases and some cephalosporinases.
|
| Pharmacology |
Cefmenoxime¿¡ ´ëÇÑ Pharmacology Á¤º¸ Cefmenoxime is a semisynthetic beta-lactam cephalosporin antibiotic with activity similar to that of cefotaxime. It has broad spectrum activity against Gram positive and Gram negative bacteria.
|
| Protein Binding |
Cefmenoxime¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 50-70%
|
| Half-life |
Cefmenoxime¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 1 hour
|
| Absorption |
Cefmenoxime¿¡ ´ëÇÑ Absorption Á¤º¸ Bioavailability is approximately 100% following intramuscular injection.
|
| Pharmacokinetics |
Cefmenoxime HClÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ºÐÆ÷ :
- ºÐÆ÷¿ëÀû : 0.21 L/kg
- ´ãÁó¿¡ ¸Å¿ì °í³óµµ·Î ºÐÆ÷ÇÏ¸ç ¼öÆ÷, »À, ½ÉÀå, ´ã³¶, ±ÙÀ°, Ȱ¾×À» Æ÷ÇÔÇÏ¿© ü³» Á¶Á÷ ¹× ü¾×¿¡ ³Î¸® ºÐÆ÷ÇÑ´Ù.
- ¼ö¸·¿¡ ¿°ÁõÀÌ ÀÖ´Â °æ¿ì ³úô¼ö¾×À¸·Î ºÐÆ÷ÇÑ´Ù.
- ÅÂ¹Ý Åë°ú, À¯Áó ºÐºñ
- ´Ü¹é°áÇÕ : 77%
- ´ë»ç : °ÅÀÇ ´ë»çµÇÁö ¾Ê´Â´Ù.
- ¹Ý°¨±â : 1-1.6 ½Ã°£
- Ç÷ÁßÃÖ°í³óµµ µµ´Þ½Ã°£ : ±ÙÀ°ÁÖ»ç : ¾à 40ºÐ
- ¼Ò½Ç : ÁÖ·Î ¹Ìº¯Èü·Î ½Å¹è¼³(67-86%)µÇ¸ç, 11%´Â º¯¹è¼³µÈ´Ù.
|
| Biotransformation |
Cefmenoxime¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not appreciably metabolized.
|
| Toxicity |
Cefmenoxime¿¡ ´ëÇÑ Toxicity Á¤º¸ Information on cefmenoxime overdosage in humans is not available. However, with other b-lactam antibiotics, adverse effects following overdosage have included nausea, vomiting, epigastric distress, diarrhea, and convulsions.
|
| Drug Interactions |
Cefmenoxime¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
Cefmenoxime¿¡ ´ëÇÑ Description Á¤º¸ Cefmenoxime is a third-generation cephalosporin antibiotic. [Wikipedia]
|
| Dosage Form |
Cefmenoxime¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Powder, for solution IntramuscularPowder, for solution Intravenous
|
| Drug Category |
Cefmenoxime¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Bacterial Agents
|
| Smiles String Canonical |
Cefmenoxime¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CON=C(C(=O)NC1C2SCC(CSC3=NN=NN3C)=C(N2C1=O)C(O)=O)C1=CSC(N)=N1
|
| Smiles String Isomeric |
Cefmenoxime¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CO\N=C(C(=O)N[C@H]1[C@H]2SCC(CSC3=NN=NN3C)=C(N2C1=O)C(O)=O)/C1=CSC(N)=N1
|
| InChI Identifier |
Cefmenoxime¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C16H17N9O5S3/c1-24-16(20-22-23-24)33-4-6-3-31-13-9(12(27)25(13)10(6)14(28)29)19-11(26)8(21-30-2)7-5-32-15(17)18-7/h5,9,13H,3-4H2,1-2H3,(H2,17,18)(H,19,26)(H,28,29)/b21-8+/t9-,13-/m1/s1/f/h19,28H,17H2
|
| Chemical IUPAC Name |
Cefmenoxime¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2023-02-15
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|
|
|